Arvinas

Yahoo Finance • 2 months ago

Arvinas Q4 2025 Earnings Preview

* Arvinas (ARVN [https://seekingalpha.com/symbol/ARVN]) is scheduled to announce Q4 earnings results on Tuesday, February 24th, before market open. The consensus EPS Estimate is -$0.57 [https://seekingalpha.com/symbol/ARVN/earnings/estim... Full story

Yahoo Finance • 2 months ago

Indian textile maker Welspun's profit nearly wiped out on US tariff-led slowdown

Feb 12 (Reuters) - Indian textile maker Welspun Living, which exports to global retailers including Walmart and Tesco, posted a slump in ‌its quarterly profit on Thursday, as a U.S. tariff-triggered slowdown ‌in exports squeezed its margin... Full story

Yahoo Finance • 2 months ago

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas... Full story

Yahoo Finance • 4 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 –... Full story

Yahoo Finance • 5 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D... Full story

Yahoo Finance • 5 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepd... Full story

Yahoo Finance • 5 months ago

Arvinas outlines plan for $100M share buyback and targets sub-$75M quarterly run rate amid pipeline expansion

Earnings Call Insights: Arvinas, Inc. (ARVN) Q3 2025 MANAGEMENT VIEW * John Houston, Chairperson, CEO & President, stated that the third quarter marked "a dynamic and productive period for Arvinas marked by meaningful progress across b... Full story

Yahoo Finance • 5 months ago

Arvinas GAAP EPS of -$0.48, revenue of $41.9M

* Arvinas press release [https://seekingalpha.com/pr/20293952-arvinas-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (ARVN [https://seekingalpha.com/symbol/ARVN]): Q3 GAAP EPS of -$0.48. * Revenue of $41.9M... Full story

Yahoo Finance • 6 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of ARV-806 from other G12D t... Full story

Yahoo Finance • 6 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-8... Full story

Yahoo Finance • 6 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestr... Full story

Yahoo Finance • 6 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials – – After 14 days of... Full story

Yahoo Finance • 6 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, includi... Full story

Yahoo Finance • 7 months ago

Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipR... Full story

Yahoo Finance • 7 months ago

Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Amazon.com(AMZN)... Full story

Yahoo Finance • 7 months ago

Arvinas announces $100M share repurchase program

* Arvinas (NASDAQ:ARVN [https://seekingalpha.com/symbol/ARVN]) said on Wednesday that its board has authorized and approved [https://seekingalpha.com/filing/10426629] a share repurchase program for the repurchase of up to $100M of the cu... Full story

Yahoo Finance • 7 months ago

Arvinas To Cut Jobs, Out-License Vepdegestrant, And Launch $100 Mln Stock Buyback Plan

(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced plans to jointly select a third party for the out-licensing and commercialization of vepdegestrant. As part of its operational streamlining, Arvinas will reduce its workforce... Full story

Yahoo Finance • 7 months ago

Arvinas, Pfizer to outlicense commercialization of cancer asset vepdegestrant

[Empty licensing agreement application form and pen.] designer491/iStock via Getty Images * Arvinas (NASDAQ:ARVN [https://seekingalpha.com/symbol/ARVN]) and Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) have decided to outlice... Full story

Yahoo Finance • 7 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 202... Full story

Yahoo Finance • 7 months ago

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participat... Full story